Hypomethylating agents alone or in combination with venetoclax in very elderly acute myeloid leukemia patients: less treatment, better care?

Tarantini F; Contento C; Vigna E; Carluccio V; Greco G; Pasciolla C; Ciuffreda L; Rossi G; Urbano MA; D'Ambrosio A; Aprile L; Gagliardi VP; Delia M; Attolico I; Carluccio P; Federico V; Bruzzese A; Di Renzo N; Gentile M; Tarantini G; Mele A; Guarini A; Melillo LMA; Carella AM; Pastore D; Frigeri F; Maggi A; Cumbo C; Specchia G; Musto P; Albano F

doi:10.1007/s00277-026-06737-3

← 뒤로

Hypomethylating agents alone or in combination with venetoclax in very elderly acute myeloid leukemia patients: less treatment, better care?

Annals of hematology 2026 Vol.105(1) p. 1

Tarantini F, Contento C, Vigna E, Carluccio V, Greco G, Pasciolla C, Ciuffreda L, Rossi G, Urbano MA, D'Ambrosio A, Aprile L, Gagliardi VP, Delia M, Attolico I, Carluccio P, Federico V, Bruzzese A, Di Renzo N, Gentile M, Tarantini G, Mele A, Guarini A, Melillo LMA, Carella AM, Pastore D, Frigeri F, Maggi A, Cumbo C, Specchia G, Musto P, Albano F

PMC 전문 ↗ 원문 ↗ DOI ↗ BibTeX ↓ RIS ↓

📝 환자 설명용 한 줄

Hypomethylating agents (HMA) alone or in combination with venetoclax (VEN) are a mainstay for disease control in elderly acute myeloid leukemia (AML).

이 논문을 인용하기

BibTeX ↓ RIS ↓

APA Tarantini F, Contento C, et al. (2026). Hypomethylating agents alone or in combination with venetoclax in very elderly acute myeloid leukemia patients: less treatment, better care?. Annals of hematology, 105(1), 1. https://doi.org/10.1007/s00277-026-06737-3

MLA Tarantini F, et al.. "Hypomethylating agents alone or in combination with venetoclax in very elderly acute myeloid leukemia patients: less treatment, better care?." Annals of hematology, vol. 105, no. 1, 2026, pp. 1.

PMID 41521357

DOI 10.1007/s00277-026-06737-3

Abstract

Hypomethylating agents (HMA) alone or in combination with venetoclax (VEN) are a mainstay for disease control in elderly acute myeloid leukemia (AML). We evaluated the non-inferiority of HMA monotherapy compared to HMA/VEN combination in 227 AML patients aged ≥ 75 years receiving HMA or HMA/VEN combination. No difference in overall survival (OS) was observed between the two groups, with HMA monotherapy demonstrating statistical non-inferiority. HMA-treated patients with favorable performance status had longer OS. The HMA/VEN group experienced higher mortality and worse QoL. HMA monotherapy offers comparable survival outcomes to HMA/VEN with reduced toxicity in elderly AML patients.

MeSH Terms

Humans; Bridged Bicyclo Compounds, Heterocyclic; Leukemia, Myeloid, Acute; Sulfonamides; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Male; Female; Survival Rate; Treatment Outcome; Decitabine; Retrospective Studies